ArticleProstate cancer and prostatic diseases2026

Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study.

Thomas Büttner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.